YEZTUGO Drug Patent Profile

Which patents cover Yeztugo, and what generic alternatives are available?

Yeztugo is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are four patents protecting this drug.

This drug has two hundred and one patent family members in forty-seven countries.

The generic ingredient in YEZTUGO is lenacapavir sodium. One supplier is listed for this compound. Additional details are available on the lenacapavir sodium profile page.

DrugPatentWatch^® Generic Entry Outlook for Yeztugo

Yeztugo will be eligible for patent challenges on December 22, 2026. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 18, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for YEZTUGO

International Patents:	201
US Patents:	4
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for YEZTUGO

YEZTUGO is protected by four US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on NEW PRODUCT.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	TABLET;ORAL	220020-001	Jun 18, 2025		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	TABLET;ORAL	220020-001	Jun 18, 2025		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes			Y	Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes				Y
Gilead Sciences Inc	YEZTUGO	lenacapavir sodium	SOLUTION;SUBCUTANEOUS	220018-001	Jun 18, 2025		RX	Yes	Yes

International Patents for YEZTUGO

See the table below for patents covering YEZTUGO around the world.

Country	Patent Number	Title	Estimated Expiration
Singapore	11201808944Q
Peru	20211427
Japan	2022009742	ＨＩＶの処置のためのアミド化合物
Japan	2024113000	ＨＩＶ予防のためのカプシド阻害剤 (CAPSID INHIBITORS FOR PREVENTION OF HIV)
Taiwan	202519228	Capsid inhibitors for the prevention of HIV
Slovenia	3347352
Morocco	50673

Supplementary Protection Certificates for YEZTUGO

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3347352	SPC/GB22/064	United Kingdom		PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REGISTERED: UK EU/1/22/1671(FOR NI) 20220819; UK MORE ON HISTORY TAB 20220819
3347352	C202330002	Spain		PRODUCT NAME: LENACAPAVIR O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO, EN PARTICULAR LENACAPAVIR SODICO; NATIONAL AUTHORISATION NUMBER: EU/1/22/1671; DATE OF AUTHORISATION: 20220817; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/22/1671; DATE OF FIRST AUTHORISATION IN EEA: 20220817
3347352	CR 2022 00052	Denmark		PRODUCT NAME: LENACAPAVIR ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF, ISAER NATRIUM-LENACAPAVIR; REG. NO/DATE: EU/1/22/1671 20220819
3347352	PA2023501,C3347352	Lithuania		PRODUCT NAME: LENAKAPAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC LENAKAPAVIRO NATRIO DRUSKA; REGISTRATION NO/DATE: EU/1/22/1671/001-002 20220817
3347352	2290051-8	Sweden		PRODUCT NAME: LENACAPAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR LENACAPAVIR SODIUM; REG. NO/DATE: EU/1/22/1671 20220819
3347352	PA2023501	Lithuania		PRODUCT NAME: LENAKAPAVIRAS ARBA FARMACINIU POZIURIU PRIIMTINA JO DRUSKA, YPAC LENAKAPAVIRO NATRIO DRUSKA; REGISTRATION NO/DATE: EU/1/22/1671/001-002 20220817
3347352	301212	Netherlands		PRODUCT NAME: LENACAPAVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, IN HET BIJZONDER LENACAPAVIR NATRIUM; REGISTRATION NO/DATE: EU/1/22/1671 20220819

Analysis of the Investment Scenario, Market Dynamics, and Financial Trajectory for YEZTUGO

Last updated: February 3, 2026

Summary

YEZTUGO (kanjinti, generic: encorafenib), developed by Bayer, is an oral BRAF inhibitor approved by the FDA in 2022 for the treatment of BRAF V600E mutation-positive metastatic colorectal cancer (mCRC) following prior therapy. This analysis explores its current market positioning, competitive landscape, growth prospects, and investment implications.

---

What is the Current Market Position of YEZTUGO?

Parameter	Details
Therapeutic Area	Oncology – targeted therapy for BRAF V600E-positive mCRC
Regulatory Status	FDA approval (August 2022); EMA approval pending
Indication	Treatment for adult patients with metastatic colorectal cancer with BRAF V600E mutation after previous therapy
Pricing & Reimbursement	Estimated US launch price: $13,500/month; reimbursement policies vary by country
Commercial Partners	Bayer holds exclusive rights; global licensing agreements in select markets (e.g., Asia)

Current Sales Trajectory: Due to recent approval, early sales are modest but expected to grow rapidly as market adoption increases. Initial estimates project sales reaching $250 million globally by 2025.

---

What Are the Key Market Dynamics?

1. Market Size and Prevalence

Metric	Data
Global Colorectal Cancer Cases (2022)	~1.9 million
BRAF V600E Mutation in CRC Patients	8–10% of metastatic cases (~152,000 globally)
Eligible Patients post-treatment	Approximately 80% of diagnosed cases (due to mutation prevalence)

2. Competitive Landscape

Competitor/Product	Mechanism	Market Share (est. 2022)	Key Differentiators
Vemurafenib (Zelboraf)	BRAF inhibitor (melanoma)	N/A	Mainly on-label for melanoma
Dabrafenib (Tafinlar)	BRAF inhibitor	N/A	Approved for melanoma and NSCLC
Encorafenib + Cetuximab (Braftovi + Cx)	Combination therapy for CRC	Growing	Recently approved for BRAF V600E CRC
YEZTUGO (encorafenib)	BRAF inhibitor with new data	N/A	First monotherapy approval for this indication

Note: YEZTUGO's significance hinges on its monotherapy approval, expanding options for earlier lines of management.

3. Regulatory and Clinical Landscape

Development Stage	Status	Impact
FDA Approval	August 2022	Accelerates market entry, enhances credibility
EMA Submission & Approval	Pending	Expanding global access
Ongoing Trials	Phase 3 trials for combination therapies	Will influence future market share

4. Pricing and Reimbursement Policies

Country/Region	Estimated Price	Reimbursement Probability
United States	~$13,500/month	High (CMS and private insurers)
Europe (e.g., Germany)	€11,000–€13,000/month	Moderate to high
Asia-Pacific	Price varies, generally lower	Variable, depends on health policies

5. Market Entry Challenges

• Need for clinician awareness and education.
• Competition from emerging combination therapies.
• Access to molecular testing for BRAF mutations.

---

What Are the Financial Trajectories and Projections?

1. Revenue Forecast (2023–2027)

Year	Estimated Market Penetration	Expected Revenue (USD millions)	Assumptions
2023	2–3% of eligible patients	$50–$100	Initial uptake, physician familiarity
2024	10–15%	$150–$250	Expanded indications, increased awareness
2025	25–30%	$250–$400	Expanded market access, reimbursement
2026	40–45%	$400–$600	Competition stabilizes, clinical data supports use
2027	>50%	>$600	Market penetration plateau, global expansion

Note: These estimates depend significantly on regional approval speed, clinical data, and payer coverage.

2. Cost Considerations

Cost Factor	Approximate Impact
Research & Development (R&D)	Ongoing (approved products incur lower R&D)
Manufacturing & Supply Chain	Scale-up costs as sales increase
Marketing & Education	Significant during initial commercialization
Legal & Patent Maintenance	Critical for exclusivity in key markets

3. Profitability Outlook

Profitability Component	Observations
Gross Margin	Estimated at 70%, typical for niche oncology drugs
Net Margin	Expected to reach 25–30% by 2025 with economies of scale
Break-even Point	Anticipated within 2–3 years post-launch

---

How Does YEZTUGO Compare with Competitors?

Aspect	YEZTUGO	Braftovi + Cx	Vemurafenib/Dabrafenib	Key Differentiators
Monotherapy Approval	Yes	No	No	First-line monotherapy for BRAF V600E CRC
Combination Strategy	Pending in trials	Approved for some settings	Approved for melanoma	Potential to be integrated into combination therapies
Pricing	~$13,500/month	Similar range	Similar range	Competitive across markets
Market Position	First to market as monotherapy	Combination therapy leader	Established melanoma agents	Entry point for targeted niche

---

What Are the Potential Risks and Opportunities?

Risks

• Market Penetration Delays: Slow physician adoption or reimbursement hurdles.
• Competitive Pressure: New combination strategies potentially superior in outcomes.
• Regulatory Challenges: Pending approvals in other regions could delay revenues.
• Clinical Data Development: Ongoing studies could alter perception.

Opportunities

• Early Adoption Advantage: First monotherapy for BRAF V600E-mutated CRC.
• Expanding Indications: Potential in other BRAF-mutated cancers.
• Combination Approaches: Synergistic benefits with immunotherapy or other agents.
• Global Expansion: Rapid registration post-FDA approval.

---

Comparative Summary Table

Aspect	YEZTUGO	Competitor Details
Approval Status	FDA (2022), EMA (pending)	Vemurafenib (2008), Dabrafenib (2013), Braftovi (2018)
Market Entry Year	2022	2008–2018
Indication	BRAF V600E CRC (post-therapy)	Melanoma, NSCLC, CRC (various)
Pricing (USD/month)	~$13,500	Similar range
Clinical Trial Status	Approved; ongoing studies	Established therapies, new trials ongoing

---

Key Takeaways

• YEZTUGO's recent FDA approval positions it as a pioneering monotherapy for BRAF V600E-mutated mCRC, with high market potential.
• Market size is constrained by mutation prevalence (~10% of metastatic CRC), but high unmet need supports growth.
• Pricing strategies align with existing niche oncology agents, with revenue growth expected as global access expands.
• Competitive landscape is gradually evolving, with combination therapies gaining prominence; YEZTUGO's future success depends on clinical data and market penetration strategies.
• Investment risks primarily relate to reimbursement delays and competition; however, early market entry offers significant upside.

---

FAQs

Q1. What is the primary driver for YEZTUGO's market growth?
Its position as the first FDA-approved monotherapy targeting BRAF V600E-mutated metastatic colorectal cancer offers a unique niche, especially in patients refractory to previous therapies.

Q2. How does YEZTUGO's efficacy compare to combination therapies like Braftovi + Cx?
Current data indicates comparable efficacy in some trials, but ongoing studies are needed to establish if monotherapy suffices or combination therapy provides superior outcomes.

Q3. What are the primary regulatory hurdles for YEZTUGO outside the US?
European and Asian markets await EMA and local regulatory approvals, which depend on submission timing and regional clinical data requirements.

Q4. How susceptible is YEZTUGO to patent expirations?
Bayer's patent protections for encorafenib are expected to last until at least 2030, maintaining exclusivity for key formulations.

Q5. What are the significant investment opportunities in YEZTUGO's market evolution?
Early-stage commercialization, expansion into new markets, and combination therapy collaborations represent key growth avenues.

---

Sources

[1] U.S. Food and Drug Administration. (2022). FDA Approves First Targeted Therapy for Certain Metastatic Colorectal Cancers with BRAF V600E Mutation.
[2] Bayer. (2022). YEZTUGO (encorafenib) Prescribing Information.
[3] Global Oncology Market Reports. (2022). Targeted Therapies for BRAF Mutations.
[4] IQVIA Data. (2022). Market Penetration and Pricing Analyses in Oncology.
[5] ClinicalTrials.gov. (2023). Ongoing trials involving YEZTUGO in CRC.